Peripheral blood MRD correlates with treatment benefit in CLLJune 18, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomabJune 17, 2018Leukemia, Myelodysplasia, TransplantationALL
‘Excellent’ survival with HCT despite early treatment failure in FLJune 16, 2018Lymphoma & Plasma Cell DisordersTransplantationAggressive Lymphomas
Interim PET scans identify HL patients with better outcomesJune 16, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Ivosidenib active in R/R IDH1-mutated AML patientsJune 14, 2018Leukemia, Myelodysplasia, TransplantationAML
FDA grants pembrolizumab accelerated approval for PMBCLJune 14, 2018Lymphoma & Plasma Cell DisordersPharmacyAggressive Lymphomas
Ibrutinib and venetoclax combo promising in frontline CLLJune 13, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Chemo-free combo provides potential first-line option for FLJune 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
FDA approves venetoclax for CLL/SLL with or without del 17pJune 10, 2018Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Dasatinib outcomes similar to imatinib in pediatric Ph+ ALLJune 9, 2018Leukemia, Myelodysplasia, TransplantationPediatricsTransplantationALL
Polatuzumab plus BR improves efficacy in DLBCLJune 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
